Other · developed by Latigo Biotherapeutics
LTG-305 is a drug studied in healthy participants in a trial with single-ascending dose and multiple-ascending dose cohorts.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06554574 | Phase 1 | Healthy | Completed | LTGO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy
Updated Oct 18, 2026. Something wrong or missing? Report it on the LTGO page.
See LTGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LTGO catalysts and pipeline →